Skip to content

US · PBM · BIOTECHNOLOGY

Psyence Biomedical Ltd. (PBM) intrinsic value and stock valuation

$2.97as of 2026-11-21 · Mkt cap 62.57K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Psyence Biomedical Ltd. DCF and intrinsic value

InvestorsCraft values PBM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PBM’s statements →

Healthcare · Biotechnology Toronto, ON M5H 2K1 psyencebiomed.com

How the business is doing

Fiscal 2022–2026, USD

Revenue
$0.00
20222026
Net income
-$-6.94M
20222026
Free cash flow
-$-8.64M
20222026
Total equity
$16.9M+28.7% 5y CAGRd
20212026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-6.24M-$-3.66M-$-2.75M-$-4.38M-$-330K
Net income-$-6.94M$1.01M-$-51.16M$8.01M$8.23M
EPSd—$1.77M-$-7.85M$245.2K$251.9K
Operating cash flow-$-8.14M-$-3.73M-$-2.95M-$-520K-$-840K
Capital expenditure-$-500K-$-10K-$-10K$0.00$0.00
Free cash flow-$-8.64M-$-3.74M-$-2.95M-$-520K-$-840K
Total assets$17.6M$7.32M$1.13M$258.9M$326.6M
Total debt$0.00$0.00$10.5M$690K$0.00
Net debt-$-7.44M-$-6.14M$9.69M$670K-$-430K
Total equity$16.9M$6.72M-$-10.97M$244.7M$301.6M
Cash and short-term investments$7.44M$6.14M$760K$20K$430K
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00-$0.00-$0.00$0.00$0.00
Research and development expenses$1.47M$340K$950K$1.61M$140K
Selling, general and administrative expenses$4.77M$3.32M$1.8M$1.63M$1.72M
Other expenses$10K$0.00$0.00-$-1.94M-$-1.52M
Operating expenses$6.24M$3.66M$2.75M$1.29M$330K
Cost and expenses$6.24M$3.66M$2.75M$1.29M$330K
Interest income$260K$100K$0.00$0.00$0.00
Interest expense$10K$10K$50K$0.00$0.00
Depreciation and amortization$10K$0.00$0.00$0.00$2.32M
Ebitda-$-6.92M$1.03M-$-51.11M$10.8M$10.5M
Operating income-$-6.24M-$-3.66M-$-2.75M-$-4.38M-$-330K
Total other income/expenses, net-$-700K$4.67M-$-48.41M$40K$8.56M
Income before tax-$-6.94M$1.01M-$-51.16M$8.01M$8.23M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6.94M$1.01M-$-51.16M$8.01M$8.23M
Weighted average shares outstanding$0.00$570K$6.52M$32.7M$32.7M
Weighted average diluted shares outstanding$0.00$570K$6.52M$32.7M$32.7M
Balance sheet
20262025202420232022
Cash and short-term investments$7.44M$6.14M$760K$20K$430K
Net receivables$360K$140K$40K$60K$40K
Inventory$0.00$0.00$0.00$0.00-$-40K
Total current assets$9.11M$6.56M$1.13M$1.21M$800K
Property, plant and equipment, net$10K$10K$10K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$8.45M$740K$0.00$257.7M$255M
Total non-current assets$8.46M$760K$10K$257.7M$255.3M
Total assets$17.6M$7.32M$1.13M$258.9M$326.6M
Accounts payable$230K$260K$560K$1.63M$40K
Short-term debt$0.00$0.00$10.5M$690K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$620K$590K$12.1M$14.3M$140K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$16.2M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$620K$590K$12.1M$14.3M$16.4M
Common stock$78.8M$61.8M$46.1M$258.6M$255M
Retained earnings-$-63.38M-$-56.45M-$-57.46M-$-13.9M-$-18.36M
Accumulated other comprehensive income (loss)$400K$350K$360K$0.00$0.00
Total equity$16.9M$6.72M-$-10.97M$244.7M$301.6M
Total investments$8.45M$740K$0.00$257.7M$255M
Total debt$0.00$0.00$10.5M$690K$0.00
Net debt-$-7.44M-$-6.14M$9.69M$670K-$-430K
Cash flow statement
20262025202420232022
Net income-$-6.94M$1.01M-$-51.16M-$-20K-$-1.86M
Depreciation and amortization$10K$0.00$0.00$0.00$0.00
Stock-based compensation$160K$0.00$320K$220K$330K
Change in working capital-$-1.22M-$-390K-$-1.17M-$-50K$130K
Accounts receivable-$-230K-$-100K$110K$0.00$100K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-8.14M-$-3.73M-$-2.95M-$0.00-$-1.07M
Investments in property, plant and equipment-$-500K-$-10K-$-10K$0.00$0.00
Acquisitions, net-$-4M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-4.51M-$-20K-$-10K$0.00-$-30K
Common stock issued$0.00$1.74M$0.00$0.00$256.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14M$9.15M$2.35M$0.00-$-1.63M
Net change in cash$1.31M$5.4M-$-600K-$0.00-$-3.06M
Cash at end of period$7.44M$6.14M$730K$0.00$1.76M
Operating cash flow-$-8.14M-$-3.73M-$-2.95M-$-520K-$-840K
Capital expenditure-$-500K-$-10K-$-10K$0.00$0.00
Free cash flow-$-8.64M-$-3.74M-$-2.95M-$-520K-$-840K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Psyence Biomedical Ltd.

        Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

        CEO
        Jody Aufrichtig
        Employees
        12
        Beta
        1.68

        Explore

        Frequently asked questions

        What is the intrinsic value of Psyence Biomedical Ltd. (PBM)?

        InvestorsCraft does not currently publish an intrinsic value for PBM. How the IC value is calculated.

        Is PBM undervalued?

        InvestorsCraft does not publish an undervaluation signal for PBM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.